Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Hippocampal atrophy, as evidenced using magnetic resonance imaging (MRI), is one of the most validated, easily accessible and widely used biomarkers of Alzheimer's disease (AD). However, its imperfect sensitivity and specificity have highlighted the need to improve the analysis of MRI data. Based on neuropathological data showing a differential vulnerability of hippocampal subfields to AD processes, neuroimaging researchers have tried to capture corresponding morphological changes within the hippocampus. The present review provides an overview of the methodological developments that allow the assessment of hippocampal subfield morphology in vivo, and summarizes the results of studies looking at the effects of AD and normal aging on these structures. Most studies highlighted a focal atrophy of the CA1 subfield in the early (predementia or even preclinical) stages of AD, before atrophy becomes more widespread at the dementia stage, consistent with the pathological literature. Preliminary studies have indicated that looking at this focal atrophy pattern rather than standard whole hippocampus volumetry improves diagnostic accuracy at the mild cognitive impairment (MCI) stage. However, controversies remain regarding changes in hippocampal subfield structure in normal aging and regarding correlations between specific subfield volume and memory abilities, very likely because of the strong methodological variability between studies. Overall, hippocampal subfield analysis has proven to be a promising technique in the study of AD. However, harmonization of segmentation protocols and studies on larger samples are needed to enable accurate comparisons between studies and to confirm the clinical utility of these techniques.

Key findings

Why it matters

This 2015 review reports that "most studies" found shrinkage concentrated in one part of the hippocampus, the CA1 subfield, in early Alzheimer's disease, before it spreads more widely at the dementia stage. "Preliminary studies" suggested that looking at this pattern, rather than the whole hippocampus, improves diagnostic accuracy at the mild cognitive impairment stage. The authors add that methods vary widely between studies and that standardised protocols and larger samples are needed "to confirm the clinical utility of these techniques". It is about diagnosis, not treatment.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuroscience)
Journal's citation record 3 / 4 Neuroscience: journal h-index 370 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 365 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 28.1 citations a year over 13 year(s) since 2015
Impact for its field and year 4 / 6 Cited 16.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 3 / 4 Cited 95 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Gaël Chételat: h-index 90 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 26306871)
Free to read 0 / 2 Behind a paywall — scores zero
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

de Flores, R., La Joie, R., & Chételat, G. (2015). Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. Neuroscience. https://doi.org/10.1016/j.neuroscience.2015.08.033

Vancouver

de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. Neuroscience. 2015. doi:10.1016/j.neuroscience.2015.08.033. PMID: 26306871.

BibTeX

@article{deflores2015-26306871,
  author  = {de Flores, R. and La Joie, R. and Chételat, G.},
  title   = {{Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease}},
  journal = {Neuroscience},
  year    = {2015},
  doi     = {10.1016/j.neuroscience.2015.08.033},
  pmid    = {26306871},
  url     = {https://doi.org/10.1016/j.neuroscience.2015.08.033}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis

Also tagged “disorder”

492 studies in the library carry the topic tag “disorder”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 492 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →